A brain tumor board sounds intimidating. In plain terms, it is a room full of specialists looking at one patient’s scans and slides at the same time, instead of one doctor at a time over several weeks. When a tumor sits in a difficult location — near the speech cortex, the brainstem, the optic chiasm — the decision about surgery, radiation, or watchful waiting is rarely obvious. That is exactly the situation a multidisciplinary team, or MDT, was built for.

Our team at China Medical Services coordinates this kind of review for international patients every week. And the question we hear most often is a practical one: can a patient sitting in Toronto, Dubai, or Jakarta actually get their case in front of a Chinese brain tumor board without flying first? The short answer is yes — with the right records and realistic expectations.

The Problem: Waiting Weeks for a Decision That Should Take Days

In many Western health systems, a newly diagnosed brain tumor enters a referral queue. You see a neurosurgeon. That surgeon orders a repeat MRI. Then a radiation oncology consult. Then a neuropathology review. Each appointment is separated by two to six weeks, and each specialist forms an opinion without the others in the room. By the time a plan emerges, two or three months may have passed since the first scan.

That delay has consequences. A 2019 study in Neuro-Oncology Practice found that longer intervals from imaging to treatment initiation were associated with worse functional outcomes in high-grade glioma patients. Nobody is being careless — the system is simply fragmented.

Then there is the second problem: cost. A craniotomy at a major U.S. academic center frequently runs $150,000 to $300,000 before rehabilitation, and insurance may cover only part of it. For patients without comprehensive coverage, or those in countries where advanced neurosurgery is simply unavailable, the math becomes impossible.

So patients start searching. And they find that China’s top neurosurgical centers handle volumes that most Western hospitals never approach — which raises a fair question. Does volume translate into better decisions for a complex tumor case?

Why a Brain Tumor Board in China Delivers Real Value

Not every Chinese hospital runs a genuine MDT. The ones that do tend to be the large academic centers, and their structural advantages are worth understanding before you commit to anything.

Case Volume Changes How Teams Think

Beijing Tiantan Hospital, affiliated with Capital Medical University, is one of the highest-volume neurosurgical centers in the world. It performs tens of thousands of neurosurgical procedures annually. Fudan University’s Huashan Hospital in Shanghai sits in the same tier for neurosurgery, and both appear on the Fudan Hospital Rankings specialty reputation list — which ranks China’s top 10 hospitals per specialty across 45 disciplines, including neurosurgery and oncology.

Volume matters for a specific reason. A team that sees 40 complex skull-base tumors a month develops pattern recognition that a team seeing four a month does not. When your case reaches the board, you are not the interesting rarity of the quarter. You are a familiar problem with a known playbook.

Multidisciplinary Review Happens in One Sitting

A functioning MDT at a Chinese tertiary hospital typically convenes weekly. Neurosurgery, radiation oncology, medical neuro-oncology, neuroradiology, and pathology sit together. Imaging goes up on the screen. The pathologist speaks to the molecular markers — IDH mutation status, MGMT promoter methylation, 1p/19q codeletion. The radiation oncologist comments on dose constraints. A recommendation emerges in one meeting rather than five.

For patients, this compresses a fragmented process into something closer to a single event. That is the entire point of the format.

The Cost Gap Is Structural, Not a Quality Signal

Here is the objection we hear constantly: if it costs a fraction of U.S. prices, something must be missing. The reasoning behind lower costs is not mysterious. Surgeon compensation in China is lower. Hospital overhead is lower. Implant and consumable procurement is negotiated at national scale. And high patient throughput spreads fixed costs across far more cases.

All figures are ranges. Actual pricing depends on hospital tier, tumor complexity, implant selection, ICU days, and whether you use the standard public pathway or the international department. We never quote a fixed number before a case is reviewed.

How Participation Actually Works, Step by Step

This is the part most articles skip. Here is the real sequence for an international patient.

Step 1 — Records assembly. You need your most recent MRI or CT as DICOM files, not screenshots or PDFs. You need the pathology report, and ideally the actual stained slides or paraffin blocks if a re-read is needed. You need your operative notes if you have had prior surgery, plus current medication list and recent labs.

Step 2 — Record translation and structuring. Chinese specialty teams read English, but a properly structured case summary in the hospital’s expected format dramatically speeds review. This is where sloppy submissions stall.

Step 3 — Choosing the pathway. There are three realistic options, and they are not equivalent.

Step 4 — The review itself. For a written opinion, turnaround is typically five to ten business days after complete records arrive. Incomplete records are the single biggest cause of delay.

Step 5 — Decision point. You receive a written opinion. It is a reference document, not a prescription, and it does not replace your treating physician. From there you decide whether to pursue treatment locally, in China, or elsewhere.

What the Board Cannot Do — and Who Should Not Bother